You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Rhinology

Importance of Endotyping in CRSwNP

Prof. Wytske Fokkens discusses the role of endotyping in the management of CRSwNP.
Wytske Fokkens
MD, PhD
Wytske Fokkens

Learning objectives

  • Differentiate between type 2 and non-type 2 inflammation by identifying endotype in patients with CRSwNP

Description

Wytske Fokkens, MD, PhD, shares her clinical approach to determining the endotype in patients with CRSwNP and its importance in her daily practice.

Tags
endotypeexpert insightsquality of lifedisease control
MAT-GLB-2302584 v2.0 06/2023

About this expert

Rhinology

Wytske Fokkens

MD, PhD

Professor in the Department of Otorhinolaryngology | Academic Medical Center, Amsterdam, Netherlands; Director | European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA)

See author’s profile
Wytske Fokkens

Related resources

Partnering With Patients for Clinical Decision-Making in CRSwNP
Rhinology
expert video

Partnering With Patients for Clinical Decision-Making in CRSwNP

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective
Rhinology
expert video

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future
Rhinology
expert video

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP
Rhinology
expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

Defining Mechanisms of Anosmia in CRSwNP
Rhinology
expert video

Defining Mechanisms of Anosmia in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation
Rhinology
expert video

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

ADVENT On Air | Loss of Smell in CRSwNP Patients
Rhinology
Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Remission in CRSwNP
Rhinology
Podcast

ADVENT On Air | Remission in CRSwNP

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Pulmonology
expert video

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?
Rhinology
expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?
Rhinology
expert video

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Dr. Giorgio Canonica Regarding Multidisciplinary Approach
Rhinology
expert video

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?
Rhinology
expert video

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

Connecting Type 2 Inflammation to CRSwNP
Rhinology
expert video

Connecting Type 2 Inflammation to CRSwNP

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients
Rhinology
interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission
Rhinology
expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

The Pathophysiology of Type 2 Inflammation in CRSwNP
Rhinology
interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

CRSwNP: A Chronic Type 2 Inflammatory Disease
Rhinology
expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

Importance of Endotyping in CRSwNP
Rhinology
expert video

Importance of Endotyping in CRSwNP

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FranceChange country/region